Boston Scientific Corporation (NYSE:BSX) reported upbeat earnings for the first quarter on Wednesday.
The company posted first-quarter 2026 revenues of $5.20 billion on Wednesday, slightly better than the consensus estimate of $5.17 billion, beating the management guidance of $5.22 billion-$5.31 billion.
The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 79 cents and the management guidance of 78-80 cents.
The company lowered its fiscal 2026 adjusted earnings per share guidance from $3.43-$3.49 to $3.34-$3.41, below the Wall Street estimate of $3.45.
Boston Scientific forecasts net sales growth of approximately 7%-8.5% (prior 10.5%-11.5%) in 2026 on a reported basis, and 6.5%-8% (prior 10%-11%) organically. The company also lowered 2026 sales guidance from …